CCEL 最新10-Q变化
将 CCEL 最新的定期申报(10-K/10-Q)与上一份同类型申报逐章节对比:每个章节新增/删除的段落数与原文摘录。全部为确定性文本对比——无相似度评分、无方向判断、非投资建议。
对比:10-Q · 2026-07-15 与上一份 10-Q · 2026-04-14
| 章节 | 结果 | 新增 | 删除 | 微调 | 未变 |
|---|---|---|---|---|---|
| 管理层讨论与分析 | 文字有新增/删除 | +25 | −15 | ~12 | 75 |
| 控制与程序 | 文字有新增/删除 | 0 | −1 | ~2 | 3 |
| 法律诉讼 | 文字有新增/删除 | 0 | 0 | ~1 | 1 |
| 风险因素 | 部分风险因素更新 | +1 | −1 | ~3 | 4 |
| 其他信息 | 文字有新增/删除 | 0 | 0 | ~1 | 0 |
计数单位为段落;"新增/删除"指相对上一份文件新增/删除的文字,不含方向或好坏判断。
未列出(无法可靠提取或缺失):市场风险(第3项)
代表性摘录
每个章节最多 5 条、每条约 300 字符的原文摘录,直接来自两份 SEC 文件。
管理层讨论与分析
相对上期新增的文字 · 来源:10-Q · 2026-07-15
Processing and Storage Fees. For six months ended May 31, 2026 and May 31, 2025 processing and storage fees were $15,358,559 and $15,737,607, respectively. The decrease in processing and storage fee revenue is attributable to a 3% increase in recurring annual storage fee revenue offset by a 14% decr…
Product Revenue. For the six months ended May 31, 2026, revenue from the product sales was $52,776 compared to $35,349 for the six months ended May 31, 2025.
Public Cord Blood Banking Revenue. For the six months ended May 31, 2026, revenue from the public cord blood banking sales was $47,895 compared to $124,767 for the six months ended May 31, 2025. The change in revenue is due to the volatility of customer demand.
Cost of Sales. Cost of sales for the six months ended May 31, 2026 was $3,333,151 as compared to $3,841,127 for the same period in 2025, representing a 13% decrease. Cost of sales includes wages and supplies associated with process enhancements to the existing production procedures and quality syste…
Selling, General and Administrative Expenses. Selling, general and administrative expenses for the six months ended May 31, 2026 were $9,629,846 as compared to $8,896,142 for the 2025 period representing a 8% increase. These expenses are primarily comprised of selling and marketing expenses, salarie…
相对上期删除的文字 · 来源:10-Q · 2026-04-14
Revenue. Revenue for the three months ended February 28, 2026 was $7,683,117 as compared to $7,968,880 for the same period in 2025 a decrease of 4% as a result of the reasons discussed below.
Processing and Storage Fees. For the three months ended February 28, 2026, processing and storage fees were $7,643,113 compared to $7,865,888 for the three months ended February 28, 2025. Processing and storage fee revenue is attributable to a 3% decrease in recurring annual storage fee revenue offs…
Product Revenue. For the three months ended February 28, 2026, revenue from the product sales was $38,594 compared to $20,913 for the three months ended February 28, 2025.
Public Cord Blood Banking Revenue. For the three months ended February 28, 2026, revenue from the public cord blood banking sales was $1,410 compared to $82,079 for the three months ended February 28, 2025.
Cost of Sales. Cost of sales for the three months ended February 28, 2026 was $1,656,488 as compared to $1,984,588 for the same period in 2025, representing a 17% decrease. Cost of sales includes wages and supplies associated with process enhancements to the existing production procedures and qualit…
控制与程序
相对上期删除的文字 · 来源:10-Q · 2026-04-14
deteriorate. Because of the inherent limitations in a cost-effective control system, misstatements due to error or fraud may occur and not be detected.
风险因素
相对上期新增的文字 · 来源:10-Q · 2026-07-15
The Company may not regain compliance with the continued listing requirements.
相对上期删除的文字 · 来源:10-Q · 2026-04-14
NYSE American may not accept the Company’s Plan of Compliance
如何读 10-Q 的风险因素(第 1A 项)
10-Q 的风险因素章节有三种常见形态,本页按其一分类展示:
- 指向(pointer) — 公司仅声明"无重大变化"并指向年度 10-K 的完整风险因素;本季没有自己的风险文本可对比。
- 部分更新(partial) — 公司写明"除下述外无重大变化",只更新部分风险;摘录展示的正是本季新增的内容。
- 全文重述(restated) — 本季重新给出完整风险因素。若上一季只是"指向",则无法逐段对比,本页会将其标为"本季全文重述"。
这只是对文件结构的客观描述,不构成对风险高低的判断。
数据来自 SEC EDGAR 两份申报文件的文本级对比 · 确定性计算(无 AI 生成内容)· 仅供参考 · 非投资建议